The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Good afternoon. Thank you for taking the questions, and for the update. Maybe first one, just regarding the landscape, it sounds like you're seeing
some improvement, albeit some cancellations are remaining a little bit elevated. Maybe if you could talk a little bit about what you're hearing from
customers regarding their pipelines, regarding their desire to invest and keep moving the ball forward on some of those programs?
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. And then, maybe touching on the internal issues that kind of popped up, could you provide a little bit of color on what those were and how
those have been addressed?
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Got it. All right. Maybe one last one, then I'll hop back in the queue. But I was wondering if you could give us an update on the Alloy Therapeutics
partnership.
How that's progressing? Any details there? Thank you.
Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst
: Great. Thank you.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Thank you, and good afternoon. Just a couple of questions. First, you mentioned year-over-year bookings were up 15% in the fourth quarter.
Can you give us a baseline for that? What was that number in the first, second, and third quarters? So we can put that into context.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: So, it sounded -- okay, I'm just trying to get a sense of that number outside of isolation. It sounds like it was within the typical range, perhaps the
higher end, but that's good.
Second, David, I think you said 5% to 15% revenue growth in fiscal 2024. When we think about the first half versus the second half, it sounds like
the first half would be the lower end of that range, the second half, the higher end of that range. Is that fair?
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, thank you. And then, you're getting into the AI business, certainly in the drug discovery channel. Is AI also a threat to your business? I mean,
how do you think about what AI could do to the core business? If at all, or perhaps, you can even do more with it that makes it more appealing?
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, great. Final question, which is a bit of a tougher one, but I think a relevant one. You've got a great core business, it's done well for multiple
years. You've invested in some new initiatives which, to be honest, they haven't worked out as well as planned, which happens with new initiatives.
But now, you're starting to have some pain in the core business as well from execution. So the question is, do you think you're spreading yourself
too thin? Could this Corellia business actually help to maintain the shift separate between the core and the new initiatives? Thank you.
Question: Scott Henry - ROTH Capital Partners, LLC - Analyst
: Okay, great. Thank you for the color, and thank you for taking the question.
|
